New trial
Phase 2: Raludotatug Deruxtecan, CDH6‐targeted ADC with an enzymatically cleavable linker
- Trial ID
- NCT06780085 on ClinicalTrials.gov
- Cancer type
- Non-Small Cell Lung Cancer (NSCLC)
- Stage of research
- Exploratory
- Location
- 8 Locations
- Published in
- New in Oncology - Aug 1, 2025
This randomized umbrella study by Merck Sharp & Dohme LLC assesses two investigational ADCs—raludotatug deruxtecan (CDH6-directed) and ifinatamab deruxtecan (B7-H3-targeting Topo1 toxin ADC)—versus docetaxel in patients with stage IV nonsquamous NSCLC that has progressed after standard therapy. The trial evaluates safety, tolerability, and tumor response in this novel approach for metastatic disease.
More in non-small cell lung cancer
-
Trial result · Oct 22, 2026 · NCT04905316
Canakinumab (IL-1β blockade) + cCRT and durvalumab consolidation hits 67% 24-mo PFS in unresectable stage III NSCLC -
Trial result · Oct 15, 2026 · NCT04495153
CAN-2409 + valacyclovir reports 14.3-month median OS in treated NSCLC patients; 24.5 months in a selected per-protocol group -
New trial · Oct 15, 2026 · NCT07852247
Phase 1 CyberKnife SBRT uses Synchrony respiratory motion tracking for ultra-central NSCLC -
New trial · Oct 15, 2026 · NCT07617337
Phase 1 AQUA07 allosteric ALK inhibitor (macrocyclic peptide) alone or with lorlatinib in ALK-positive NSCLC -
Trial result · Oct 8, 2026 · NCT03052608
AI volumetric brain-met response may better predict PFS in ALK+ NSCLC